MERCK KGAA
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
Phase 3
Completed
- Conditions
- Non Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1861
- Registration Number
- NCT00148798
- Locations
- π¬π§
Research Site, Wolverhampton, United Kingdom
Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 288
- Registration Number
- NCT00146640
- Locations
- π΅π±
Research Site, Wroclaw, Poland
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Phase 2
Completed
- Conditions
- Neoplasm MetastasisColorectal Cancer
- Interventions
- Biological: Cetuximab
- First Posted Date
- 2005-07-29
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 344
- Registration Number
- NCT00125034
- Locations
- πΊπ¦
Research Site, Vinnitsa, Ukraine
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)
Phase 3
Completed
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 442
- Registration Number
- NCT00122460
- Locations
- π¬π§
Research Site, Nottingham, United Kingdom
Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer
Phase 1
Completed
- Conditions
- Esophageal CancerGastric Cancer
- First Posted Date
- 2005-06-10
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 26
- Registration Number
- NCT00113581
- Locations
- π¬π§
The Royal Marsden Hospital, London, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath